Germany now has 40 Digital Health solutions that fit into the definition of a DiGA and that are made accessible to HCPs and patients through statutory health insurance reimbursement.
Below are some highlights from our Digital Health & Innovation Strategy team:
- Uptake and Growth: DiGA prescriptions tripled from 2021 to 2022 and over 80% of patients convert prescriptions into access - targeted strategies are still very needed for continuous scale-up and adoption, but uptake is growing;
- Market Concentration & Competitive Advantage: the top three manufactures now make up for 40% of total DiGAs and the top-5 DiGAs make up for 61% of prescriptions – economies of scale for early entrants are typical of a software-based product and market;
- Median Price: €552 reflecting clinical evidence and value, though prices range also based on license type and usage indications;
- Value Assessment: sound clinical evidence is required and is amongst the main cause of revoked authorization - ~1/3 of solutions achieved permanent reimbursement with solid clinical evidence but timely access is also encouraged through the fast-track, enabling 25 solutions to be accessible while still requiring them to generate value evidence within 12-months;
- Therapeutic Areas: DiGAs are covering an increasing number of therapeutic areas, enhancing usual care;
- Tech: DiGAs are not just apps but as certified (class I and IIa), clinically validated digitally-driven primarily in the hands of patients, they also include web-based applications.
Reach out to know more about our continuous monitor and work on Digital Health and DTx policies, value and access pathways and system integration and GTM strategies!
the full deck or check-out the LinkedIn post.